IntelGenx's robust and diversified product pipeline, leveraging the VersaFilm® and VetaFilmTM proprietary oral film platforms, addresses significant market opportunities and unmet patient needs

Differentiated Products

Indication
(Molecule)
Partner Formulation
Development
Clinical Filing   Launch
Pipeline versa lagrge flec Migraine - RIZAPORT®
(Rizatriptan)

 gensco

 exeltis logo
 
intro logo2

flec Erectile Dysfunction - EXORDIA®
(Tadalafil)
aquestive logo 
flec Schizophrenia
(Loxapine)
Available
 
flec Neurodegenerative Brain Diseases
(Montelukast)
Available
 
 
flec Opioid Dependence
(Buprenorphine / Naloxone)
 Endo 2018
flec Chronic Pain
(Buprenorphine)
iromed logo 
flec Treatment-Resistant Depression
(N, N-Dimethyltryptamine)
Screen Shot 2020 08 21 at 1.00.53 PM

 

Animal Health

Indication
(Molecule)
Partner Formulation
Development
Clinical Filing   Launch
Pipeline versa lagrge flec Undisclosed Screen Shot 2020 08 21 at 1.00.53 PM

 

Cannabinoids

Product
Partner Formulation
Development
Clinical Filing   Launch
Pipeline versa lagrge flec CBD  tilray
flec THC  tilray
flec THC:CBD  tilray

Pipeline Disclaimer

The information included on this site reflects IntelGenx Corp. clinical development pipeline and is not intended for promotional purposes. It includes new indications or line extensions of currently approved products that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued or delayed, or to fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of August 25, 2020. IntelGenx assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.